Knocking down Zeb1 as a mode of overcoming anoikis resistance and improving therapeutic response provides promise, wherein silencing Zeb1 in PCa cell lines leads to decreased cancer stem cell markers (CD44, CD133 and SOX2) and decreased ability to form protospheres and colonies (45). This evidence concerns the gene ZEB1 and posterior cortical atrophy.